JP2005145961A - 角結膜障害の治療剤 - Google Patents
角結膜障害の治療剤 Download PDFInfo
- Publication number
- JP2005145961A JP2005145961A JP2004307544A JP2004307544A JP2005145961A JP 2005145961 A JP2005145961 A JP 2005145961A JP 2004307544 A JP2004307544 A JP 2004307544A JP 2004307544 A JP2004307544 A JP 2004307544A JP 2005145961 A JP2005145961 A JP 2005145961A
- Authority
- JP
- Japan
- Prior art keywords
- corneal
- keratitis
- dry
- salt
- ylmethoxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 *=C(*1)NC(Cc(cc2)ccc2OCC(*2N)=*c(cc3)c2cc3O)C1=O Chemical compound *=C(*1)NC(Cc(cc2)ccc2OCC(*2N)=*c(cc3)c2cc3O)C1=O 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
【課題】 縮合複素環化合物である5−[4−(6−メトキシ−1−メチル−1H−ベンゾイミダゾール−2−イルメトキシ)ベンジル]チアゾリジン−2,4−ジオンまたはその塩の新たな医薬用途を探索すること。
【解決手段】 5−[4−(6−メトキシ−1−メチル−1H−ベンゾイミダゾール−2−イルメトキシ)ベンジル]チアゾリジン−2,4−ジオンまたはその塩は、ドライアイモデルにおいて優れた治癒促進効果を発揮するので、ドライアイ、角膜潰瘍、角膜炎、結膜炎、点状表層角膜症、角膜上皮欠損、結膜上皮欠損、乾性角結膜炎、上輪部角結膜炎、糸状角膜炎などの角結膜障害の治療剤として有用である。
【選択図】 なし
Description
5−[4−(6−メトキシ−1−メチル−1H−ベンゾイミダゾール−2−イルメトキシ)ベンジル]チアゾリジン−2,4−ジオン(本化合物)を用いた代表的な製剤例を以下に示す。
100ml中
本化合物 10mg
塩化ナトリウム 900mg
滅菌精製水 適量
100ml中
本化合物 100mg
塩化ナトリウム 800mg
リン酸水素二ナトリウム 100mg
リン酸二水素ナトリウム 適量
滅菌精製水 適量
100g中
本化合物 0.3g
流動パラフィン 10.0g
白色ワセリン 適量
角膜障害の治癒効力試験
雄性SDラットを用い、Fujiharaらの方法(Invest. Ophthalmol. Vis. Sci 42(1):96-100 (2001))に準じ、ドライアイモデルを作製した。ドライアイモデル作成後、宮田らの方法(眼科臨床医報 48(2):183-188 (1994))に準じ、角膜障害の治癒率を判定した。
雄性SDラットにネンブタールを35mg/kgの割合で腹腔内投与して全身麻酔を施した。ついで眼窩外涙腺を摘出し、2ヶ月かけて角膜障害を誘発させた。
0:染色されていない
1:染色が疎であり、各点状の染色部分は離れている
2:染色が中程度であり、点状の染色部分の一部が隣接している
3:染色が密であり、各点状の染色部分は隣接している
(結果)
生理食塩水点眼群(コントロール)における、上記各部のスコアの合計の平均値を基準(改善率:0%)にして下記計算式により算出した、本化合物の0.01%点眼群の改善率を表1に示す。なお、スコアの平均値は各8例の平均である。
上記のラットを用いた薬理試験の結果から明らかなように、5−[4−(6−メトキシ−1−メチル−1H−ベンゾイミダゾール−2−イルメトキシ)ベンジル]チアゾリジン−2,4−ジオンは、角膜障害を顕著に改善する。
Claims (3)
- 5−[4−(6−メトキシ−1−メチル−1H−ベンゾイミダゾール−2−イルメトキシ)ベンジル]チアゾリジン−2,4−ジオンまたはその塩を有効成分とする角結膜障害の治療剤。
- 角結膜障害が、ドライアイ、角膜潰瘍、角膜炎、結膜炎、点状表層角膜症、角膜上皮欠損、結膜上皮欠損、乾性角結膜炎、上輪部角結膜炎または糸状角膜炎である請求項1記載の治療剤。
- 点眼剤または眼軟膏の剤型にある請求項1記載の治療剤。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004307544A JP4217832B2 (ja) | 2003-10-24 | 2004-10-22 | 角結膜障害の治療剤 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003364864 | 2003-10-24 | ||
JP2004307544A JP4217832B2 (ja) | 2003-10-24 | 2004-10-22 | 角結膜障害の治療剤 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2005145961A true JP2005145961A (ja) | 2005-06-09 |
JP4217832B2 JP4217832B2 (ja) | 2009-02-04 |
Family
ID=34510137
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2004307544A Expired - Fee Related JP4217832B2 (ja) | 2003-10-24 | 2004-10-22 | 角結膜障害の治療剤 |
Country Status (16)
Country | Link |
---|---|
US (1) | US7358255B2 (ja) |
EP (1) | EP1679074B1 (ja) |
JP (1) | JP4217832B2 (ja) |
KR (1) | KR101154175B1 (ja) |
CN (1) | CN1870997B (ja) |
AT (1) | ATE490771T1 (ja) |
CA (1) | CA2543452C (ja) |
CY (1) | CY1111191T1 (ja) |
DE (1) | DE602004030470D1 (ja) |
DK (1) | DK1679074T3 (ja) |
ES (1) | ES2357801T3 (ja) |
PL (1) | PL1679074T3 (ja) |
PT (1) | PT1679074E (ja) |
SI (1) | SI1679074T1 (ja) |
TW (1) | TWI343256B (ja) |
WO (1) | WO2005039574A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006064825A1 (ja) * | 2004-12-14 | 2006-06-22 | Santen Pharmaceutical Co., Ltd. | ドライアイ治療剤 |
WO2009107652A1 (ja) | 2008-02-25 | 2009-09-03 | 参天製薬株式会社 | 角膜上皮バリア機能亢進剤 |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7348329B2 (en) * | 2003-10-29 | 2008-03-25 | Santen Pharmaceutical Co., Ltd. | Therapeutic agent for keratoconjunctival disorder |
CN101336113B (zh) * | 2005-11-28 | 2015-07-29 | 千寿制药株式会社 | 包括ppar激动剂的药物 |
TWI468162B (zh) | 2005-12-13 | 2015-01-11 | 英塞特公司 | 作為傑納斯激酶(JANUS KINASE)抑制劑之經雜芳基取代之吡咯并〔2,3-b〕吡啶及吡咯并〔2,3-b〕嘧啶 |
ES2393424T3 (es) | 2007-05-21 | 2012-12-21 | Senju Pharmaceutical Co., Ltd. | Agente farmacéutico que contiene un agonista de PPAR-delta |
SG10201509887UA (en) | 2007-06-13 | 2016-01-28 | Incyte Corp | Salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
CL2009001884A1 (es) * | 2008-10-02 | 2010-05-14 | Incyte Holdings Corp | Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco. |
SG176111A1 (en) | 2009-05-22 | 2011-12-29 | Incyte Corp | 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octane- or heptane-nitrile as jak inhibitors |
EA025520B1 (ru) | 2009-05-22 | 2017-01-30 | Инсайт Холдингс Корпорейшн | N-(ГЕТЕРО)АРИЛПИРРОЛИДИНОВЫЕ ПРОИЗВОДНЫЕ ПИРАЗОЛ-4-ИЛ-ПИРРОЛО[2,3-d]ПИРИМИДИНОВ И ПИРРОЛ-3-ИЛ-ПИРРОЛО[2,3-d]ПИРИМИДИНОВ В КАЧЕСТВЕ ИНГИБИТОРОВ ЯНУС-КИНАЗЫ |
WO2011028685A1 (en) * | 2009-09-01 | 2011-03-10 | Incyte Corporation | Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors |
MX347851B (es) | 2010-03-10 | 2017-05-16 | Incyte Corp | Derivados de piperidin-4-il azetidina como inhibidores de janus cinasa 1 (jak1). |
EP2574168B9 (en) | 2010-05-21 | 2016-10-05 | Incyte Holdings Corporation | Topical formulation for a jak inhibitor |
US9034884B2 (en) | 2010-11-19 | 2015-05-19 | Incyte Corporation | Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as JAK inhibitors |
WO2012068450A1 (en) | 2010-11-19 | 2012-05-24 | Incyte Corporation | Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors |
CA2839767A1 (en) | 2011-06-20 | 2012-12-27 | Incyte Corporation | Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors |
TW201313721A (zh) | 2011-08-18 | 2013-04-01 | Incyte Corp | 作為jak抑制劑之環己基氮雜環丁烷衍生物 |
UA111854C2 (uk) | 2011-09-07 | 2016-06-24 | Інсайт Холдінгс Корпорейшн | Способи і проміжні сполуки для отримання інгібіторів jak |
US9193733B2 (en) | 2012-05-18 | 2015-11-24 | Incyte Holdings Corporation | Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors |
BR112015010663B1 (pt) | 2012-11-15 | 2022-12-06 | Incyte Holdings Corporation | Formas de dosagem oral de liberação sustentada, e uso de ruxolitinib ou de sal farmaceuticamente aceitável do mesmo |
CN105189509B (zh) | 2013-03-06 | 2017-12-19 | 因赛特公司 | 用于制备jak抑制剂的方法及中间体 |
RS60469B1 (sr) | 2013-08-07 | 2020-07-31 | Incyte Corp | Dozni oblici sa produženim oslobađanjem za jak1 inhibitor |
WO2015184305A1 (en) | 2014-05-30 | 2015-12-03 | Incyte Corporation | TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1 |
US10596161B2 (en) | 2017-12-08 | 2020-03-24 | Incyte Corporation | Low dose combination therapy for treatment of myeloproliferative neoplasms |
WO2019152374A1 (en) | 2018-01-30 | 2019-08-08 | Incyte Corporation | Processes for preparing (1 -(3-fluoro-2-(trifluoromethyl)isonicotinyl)piperidine-4-one) |
MX2022012285A (es) | 2018-03-30 | 2023-08-15 | Incyte Corp | Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de actividad de la cinasa janus (jak). |
US11833155B2 (en) | 2020-06-03 | 2023-12-05 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3769066D1 (de) | 1986-08-28 | 1991-05-08 | Sanwa Kagaku Kenkyusho Co | Hydantoin-derivate zur behandlung von komplikationen bei diabetes. |
JP3072227B2 (ja) | 1994-08-01 | 2000-07-31 | 株式会社クボタ | 田植機の粉粒体供給装置 |
JP3603129B2 (ja) | 1994-12-28 | 2004-12-22 | 株式会社三和化学研究所 | 糖尿病性角膜症の治療剤 |
IL118474A (en) * | 1995-06-01 | 2001-08-08 | Sankyo Co | Benzimideol derivatives and pharmaceutical preparations containing them |
US6114526A (en) | 1996-07-01 | 2000-09-05 | Dr. Reddy's Research Foundation | Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases |
US5885997A (en) | 1996-07-01 | 1999-03-23 | Dr. Reddy's Research Foundation | Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases |
US6372750B2 (en) | 1996-07-01 | 2002-04-16 | Dr. Reddy's Research Foundation | Heterocyclic compounds, process for their preparation and pharmaceutical compounds containing them and their use in the treatment of diabetes and related diseases |
IL142649A (en) | 1996-12-31 | 2004-12-15 | Reddy Research Foundation | Azole derivatives |
EP0909558A3 (en) * | 1997-08-29 | 1999-10-27 | Santen Pharmaceutical Co., Ltd. | Chroman derivative containing ophthalmic solution |
JPH11130675A (ja) | 1997-08-29 | 1999-05-18 | Santen Pharmaceut Co Ltd | クロマン誘導体含有点眼液 |
JP2001039976A (ja) * | 1999-05-24 | 2001-02-13 | Sankyo Co Ltd | 縮合複素環化合物の塩酸塩 |
TWI284533B (en) * | 1999-05-24 | 2007-08-01 | Sankyo Co | Pharmaceutical composition for treating hyperglycemia, impaired glucose tolerance, diabetes complications and for improving insulin resistant |
TWI260321B (en) | 1999-09-22 | 2006-08-21 | Bristol Myers Squibb Co | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method |
JP2002220336A (ja) | 2000-11-22 | 2002-08-09 | Sankyo Co Ltd | 縮合複素環化合物の塩酸塩を含有する糖尿病の予防薬、治療薬 |
JP4090013B2 (ja) | 2000-12-26 | 2008-05-28 | 第一三共株式会社 | 利尿剤及びインスリン抵抗性改善剤を含有する医薬組成物 |
US7348329B2 (en) | 2003-10-29 | 2008-03-25 | Santen Pharmaceutical Co., Ltd. | Therapeutic agent for keratoconjunctival disorder |
-
2004
- 2004-10-22 ES ES04793171T patent/ES2357801T3/es active Active
- 2004-10-22 PT PT04793171T patent/PT1679074E/pt unknown
- 2004-10-22 US US10/576,719 patent/US7358255B2/en not_active Expired - Fee Related
- 2004-10-22 CN CN2004800309819A patent/CN1870997B/zh not_active Expired - Fee Related
- 2004-10-22 AT AT04793171T patent/ATE490771T1/de active
- 2004-10-22 EP EP04793171A patent/EP1679074B1/en not_active Not-in-force
- 2004-10-22 DE DE602004030470T patent/DE602004030470D1/de active Active
- 2004-10-22 CA CA2543452A patent/CA2543452C/en not_active Expired - Fee Related
- 2004-10-22 JP JP2004307544A patent/JP4217832B2/ja not_active Expired - Fee Related
- 2004-10-22 DK DK04793171.2T patent/DK1679074T3/da active
- 2004-10-22 TW TW093132101A patent/TWI343256B/zh not_active IP Right Cessation
- 2004-10-22 PL PL04793171T patent/PL1679074T3/pl unknown
- 2004-10-22 KR KR1020067009936A patent/KR101154175B1/ko not_active IP Right Cessation
- 2004-10-22 WO PCT/JP2004/016063 patent/WO2005039574A1/ja not_active Application Discontinuation
- 2004-10-22 SI SI200431607T patent/SI1679074T1/sl unknown
-
2011
- 2011-02-18 CY CY20111100206T patent/CY1111191T1/el unknown
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006064825A1 (ja) * | 2004-12-14 | 2006-06-22 | Santen Pharmaceutical Co., Ltd. | ドライアイ治療剤 |
WO2009107652A1 (ja) | 2008-02-25 | 2009-09-03 | 参天製薬株式会社 | 角膜上皮バリア機能亢進剤 |
JP2009227668A (ja) * | 2008-02-25 | 2009-10-08 | Santen Pharmaceut Co Ltd | 角膜上皮バリア機能亢進剤 |
RU2484848C2 (ru) * | 2008-02-25 | 2013-06-20 | Сантен Фармасьютикал Ко., Лтд. | Агент для усиления барьерной функции эпителия роговицы |
Also Published As
Publication number | Publication date |
---|---|
KR101154175B1 (ko) | 2012-06-14 |
TWI343256B (en) | 2011-06-11 |
JP4217832B2 (ja) | 2009-02-04 |
ES2357801T3 (es) | 2011-04-29 |
PL1679074T3 (pl) | 2011-05-31 |
EP1679074A4 (en) | 2009-03-25 |
US7358255B2 (en) | 2008-04-15 |
EP1679074B1 (en) | 2010-12-08 |
WO2005039574A8 (ja) | 2005-06-23 |
CN1870997B (zh) | 2011-05-04 |
DE602004030470D1 (de) | 2011-01-20 |
CY1111191T1 (el) | 2015-06-11 |
EP1679074A1 (en) | 2006-07-12 |
CA2543452C (en) | 2012-03-13 |
PT1679074E (pt) | 2011-03-03 |
SI1679074T1 (sl) | 2011-04-29 |
ATE490771T1 (de) | 2010-12-15 |
CN1870997A (zh) | 2006-11-29 |
DK1679074T3 (da) | 2011-03-21 |
US20070060628A1 (en) | 2007-03-15 |
KR20060100440A (ko) | 2006-09-20 |
TW200518750A (en) | 2005-06-16 |
CA2543452A1 (en) | 2005-05-06 |
WO2005039574A1 (ja) | 2005-05-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4217832B2 (ja) | 角結膜障害の治療剤 | |
EP1884234B1 (en) | Prophylactic or therapeutic agent for corneal and conjunctival disorder | |
JP4922588B2 (ja) | 角結膜障害治療剤 | |
US20070054943A1 (en) | Therapeutic agent for keratoconjunctival disorder | |
US7348329B2 (en) | Therapeutic agent for keratoconjunctival disorder | |
JP5087233B2 (ja) | 角結膜障害の予防または治療剤 | |
JP2006104199A (ja) | 角結膜障害治療剤 | |
RU2423127C2 (ru) | Терапевтическое средство против роговично-конъюнктивального нарушения | |
JP2005162735A (ja) | 角結膜障害治療剤 | |
JP2005350451A (ja) | 角結膜障害治療剤 | |
EP1790338A1 (en) | Therapeutic agent for keratoconjunctiva disorder | |
JP2007291091A (ja) | 角結膜障害治療剤 | |
EP1872783B1 (en) | Therapeutic agent for corneal/conjunctival disorder | |
JP4697027B2 (ja) | 角結膜障害治療剤 | |
JP2007182435A (ja) | 角結膜障害治療剤 | |
WO2007114315A1 (ja) | 角結膜障害治療剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20060223 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080624 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080818 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20080930 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20081027 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111121 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20121121 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20131121 Year of fee payment: 5 |
|
LAPS | Cancellation because of no payment of annual fees |